ARKG vs VXX
ARK Genomic Revolution ETF vs iPath Series B S&P 500 VIX Short-Term Futures ETN
ARKG$47.17
ARK Genomic Revolution ETF
Companies advancing genomics and molecular biology.
Expense: 0.75%Yield: 0.00%
VXX$17.91
iPath Series B S&P 500 VIX Short-Term Futures ETN
VIX short-term futures, hedge / speculation.
Expense: 0.89%Yield: 0.00%
Quick take
- • ARKG has the lower expense ratio at 0.75% vs 0.89% for VXX.
Side-by-side metrics
| Metric | ARKG | VXX |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.75% | 0.89% |
Dividend yield Trailing 12-month yield. | 0.00% | 0.00% |
AUM Assets under management — bigger funds are typically more liquid. | $2.21B | $566M |
YTD return | 66.55% | -28.15% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 2.11 | -58.66 |
P/E ratio | — | — |
Last price | $47.17 | $17.91 |
Inception | — | — |
Issuer | ARK | Barclays |
ARKG top holdings
Top holdings · ARKG
| TWST | Twist Bioscience Corp | 8.75% |
| TXG | 10x Genomics Inc Ordinary Shares - Class A | 8.73% |
| TEM | Tempus AI Inc Class A common stock | 8.36% |
| ABSI | Absci Corp | 5.56% |
| CRSP | CRISPR Therapeutics AG | 5.22% |
| GH | Guardant Health Inc | 4.88% |
| NTRA | Natera Inc | 4.71% |
| ILMN | Illumina Inc | 4.69% |
| LLY | Eli Lilly and Co | 3.92% |
| BEAM | Beam Therapeutics Inc | 3.69% |
Sector breakdown · ARKG
Healthcare100.0%
VXX top holdings
Holdings data unavailable for VXX.
About ARKG
ARKG (ARK Genomic Revolution ETF) is Companies advancing genomics and molecular biology. Managed by ARK, the fund carries $2.2B in assets under management, an expense ratio of 0.75%. Its largest holding is Twist Bioscience Corp (TWST), which represents 8.7% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.
About VXX
VXX (iPath Series B S&P 500 VIX Short-Term Futures ETN) is VIX short-term futures, hedge / speculation. Managed by Barclays, the fund carries $566M in assets under management, an expense ratio of 0.89%.